Myasthenia gravis
We correct the autoimmune response in myasthenia, restoring neuromuscular transmission without suppressing general immunity.
About the disease
Myasthenia gravis is an autoimmune disease where antibodies disrupt the signal transmission from nerve to muscle, causing pathological muscle weakness and fatigue.
T-cell autoimmunotherapy selectively acts on the pathogenic immune cells underlying the disease without depressing overall immunity.
Selectivity
Only pathogenic cells are suppressed.
No immunosuppression
General immunity is preserved.
Muscle strength
Reduction of weakness and fatigue.
T-cell vaccination
The method aims to stimulate immune reactions selectively directed at inactivating pathogenic autoimmune T-lymphocytes.
Collection and isolation
Autoaggressive T-lymphocytes — cells attacking the body's own tissues — are isolated from your blood.
Vaccine preparation
The isolated cells are processed and used to create a personalized T-cell vaccine.
Vaccination
Administering the vaccine triggers a regulatory immune response that selectively suppresses only the pathogenic cell clones.
Monitoring and support
Inflammatory activity decreases without suppressing general immunity; the course is adjusted based on dynamics.
Other directions
Multiple sclerosis
Selective inactivation of aggressive lymphocytes to protect the myelin sheath of nerve fibers.
Rheumatoid arthritis
Relief of joint inflammation and restoration of mobility without suppressing general immunity.
Scleroderma
Correction of the immune response to stop excessive collagen production and protect internal organs.
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.